{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:20:50Z","timestamp":1761744050332},"reference-count":25,"publisher":"Japanese Society of Internal Medicine","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2014]]},"DOI":"10.2169\/internalmedicine.53.2578","type":"journal-article","created":{"date-parts":[[2014,12,14]],"date-time":"2014-12-14T23:19:11Z","timestamp":1418599151000},"page":"2801-2804","source":"Crossref","is-referenced-by-count":3,"title":["Molecular Response to Nilotinib in a Patient with Imatinib-intolerant e19a2-positive Chronic Myeloid Leukemia"],"prefix":"10.2169","volume":"53","author":[{"given":"Tomohiro","family":"Kajiguchi","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Tosei General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Okuno","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Tosei General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihito","family":"Ohno","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Tosei General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Hematology, Fujita Health University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Saglio G, Guerrasio A, Rosso C, et al. New type of Bcr\/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 76: 1819-1824, 1990.","DOI":"10.1182\/blood.V76.9.1819.bloodjournal7691819"},{"key":"2","unstructured":"2. Pane F, Frigeri F, Sindona M, et al. Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR\/ABL with C3\/A2 junction). Blood 88: 2410-2414, 1996."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Briz M, Vilches C, Cabrera R, Fores R, Fernandez MN. Typical chronic myelogenous leukemia with e19a2 junction BCR\/ABL transcript. Blood 90: 5024-5025, 1997.","DOI":"10.1182\/blood.V90.12.5024"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. How GF, Tan LT, Lim LC. Chronic myeloid leukemia with e19a2 (c3a2) BCR\/ABL fusion junction--is it truly a benign disease? Leukemia 12: 1166-1167, 1998.","DOI":"10.1038\/sj.leu.2401055"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Muller MC, Gattermann N, Lahaye T, et al. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha\/ara-C. Leukemia 17: 2392-2400, 2003.","DOI":"10.1038\/sj.leu.2403157"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Wilson GA, Vandenberghe EA, Pollitt RC, et al. Are aberrant BCR-ABL transcripts more common than previously thought? Br J Haematol 111: 1109-1111, 2000.","DOI":"10.1046\/j.1365-2141.2000.02471.x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122: 872-884, 2013.","DOI":"10.1182\/blood-2013-05-501569"},{"key":"8","unstructured":"8. The National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0. 2011. http:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/dlocs\/ctcaev3.pdf. Accessed April 14, 2011."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Ono T, Miyawaki S, Kimura F, et al. European BCR-ABL1 mutations in patients with imatinib-resistant Philadelphia chromosome-positive leukemia by use of the PCR-Invader assay. Leuk Res 35: 598-603, 2011.","DOI":"10.1016\/j.leukres.2010.12.006"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Osumi K, Fukui T, Kiyoi H, et al. Rapid screening of leukemia fusion transcripts in acute leukemia by real-time PCR. Leuk Lymphoma 43: 2291-2299, 2002.","DOI":"10.1080\/1042819021000040206"},{"key":"11","unstructured":"11. Ito T. CML with mu-BCR\/ABL mRNA: clinical characteristics of our three cases and 26 reported cases. Rinsho Ketsueki (The Japanese Journal of Clinical Hematology) 44: 234-241, 2003 (in Japanese)."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Lee JJ, Kim HJ, Kim YJ, et al. Imatinib induces a cytogenetic response in blast crisis or interferon failure chronic myeloid leukemia patients with e19a2 BCR-ABL transcripts. Leukemia 18: 1539-1540, 2004.","DOI":"10.1038\/sj.leu.2403454"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Popovici C, Charbonnier A, Gisserot O, et al. Y253H mutation appearing in a micro-BCR-ABL (e19a2) CML. Leuk Res 32: 361-362, 2008.","DOI":"10.1016\/j.leukres.2007.03.001"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Oshikawa G, Kurosu T, Arai A, Murakami N, Miura O. Clonal evolution with double Ph followed by tetraploidy in imatinib-treated chronic myeloid leukemia with e19a2 transcript in transformation. Cancer Genet Cytogenet 199: 56-61, 2010.","DOI":"10.1016\/j.cancergencyto.2010.01.018"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Bennour A, Beaufils N, Sennana H, Meddeb B, Saad A, Gabert J. E355G mutation appearing in a patient with e19a2 chronic myeloid leukaemia resistant to imatinib. J Clin Pathol 63: 737-740, 2010.","DOI":"10.1136\/jcp.2010.078311"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Cea M, Cirmena G, Garuti A, et al. A T315I mutation in e19a2 BCR\/ABL1 chronic myeloid leukemia responding to dasatinib. Leuk Res 34: e240-e242, 2010.","DOI":"10.1016\/j.leukres.2010.03.036"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Martin SE, Sausen M, Joseph A, Kingham BF. Chronic myeloid leukemia with e19a2 atypical transcript: early imatinib resistance and complete response to dasatinib. Cancer Genet Cytogenet 201: 133-134, 2010.","DOI":"10.1016\/j.cancergencyto.2010.05.012"},{"key":"18","unstructured":"18. Langabeer SE, McCarron SL, Kelly J, et al. Chronic myeloid leukemia with e19a2 BCR-ABL1 transcripts and marked thrombocytosis: the role of molecular monitoring. Case Rep Hematol 2012: 458716, 2012."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Langabeer SE, McCarron SL, Carroll P, Kelly J, O'Dwyer M, Conneally E. Molecular response to first line nilotinib in a patient with e19a2 BCR-ABL1 chronic myeloid leukemia. Leuk Res 35: e169-e170, 2011.","DOI":"10.1016\/j.leukres.2011.05.010"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7: 129-141, 2005.","DOI":"10.1016\/j.ccr.2005.01.007"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Golemovic M, Verstovsek S, Giles F, et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has <i>in vitro<\/i> activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res 11: 4941-4947, 2005.","DOI":"10.1158\/1078-0432.CCR-04-2601"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Cortes JE, Hochhaus A, le Coutre PD, et al. Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib. Blood 117: 5600-5606, 2011.","DOI":"10.1182\/blood-2010-11-318949"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 26: 2197-2203, 2012.","DOI":"10.1038\/leu.2012.134"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Greco M, Caocci G, La Nasa G. Early complete molecular response to first-line nilotinib in two patients with chronic myeloid leukemia carrying the p230 transcript. Case Rep Hematol 2013: 871476, 2013.","DOI":"10.1155\/2013\/871476"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Deininger MW, Goldman JM, Nicholas Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 90: 3691-3698, 1997.","DOI":"10.1182\/blood.V90.9.3691"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/53\/24\/53_53.2578\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T17:52:33Z","timestamp":1621446753000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/53\/24\/53_53.2578\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":25,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.53.2578","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}